Prevenar 13 – a vaccine of choice in prophylaxis of pneumococcal infections in immunocompromised patients

Czech version

Authors: M. Bortlík
Authors‘ workplace: Klinické a výzkumné centrum pro střevní záněty ISCARE I. V. F. a. s., 1. LF UK v Praze a Interní klinika 1. LF UK a ÚVN, Praha
Published in: Gastroent Hepatol 2014; 68(4): 373-375
Category: Drug Profile

Sources

1. Chlíbek R. Očkování rizikových skupin pacientů proti pneumokokovým infekcím. Medicína po promoci 2013; 14: 44–48.

2. Clutterbuck EA, Lazarus R, Yu LM et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis 2012; 205(9): 1408–1416. doi: 10.1093/infdis/jis212.

3. De Roux A, Schmöle-Thoma B, Siber GR et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008; 46(7): 1015–1023.

4. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009; 9(3): 213–220. doi: 10.1038/nri2494.

5. Stehlík J, Mareš K, Lukáš M et al. Doporučení pro vakcinaci nemocných s Crohnovou chorobou a ulcerózní kolitidou na imunosupresivní a biologické léčbě. Ces a Slov Gastroent a Hepatol 2010; 64(1): 40–48.

6. Rahier JF, Magro F, Abreu C et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014; 8(6): 443–468. doi: 10.1016/j.crohns.2013.12.013.

7. Fiorino G, Peyrin-Biroulet L, Naccarato P et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis 2012; 18(6): 1042–1047. doi: 10.1002/ibd.21800.

8. Jackson LA, Gurtman A, van Cleeff M et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013; 31(35): 3577–3584. doi: 10.1016/j.vaccine.2013.04.085.

9. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 2012; 61(40): 816–819.

10. Česká vakcinologická společnost ČLS JEP. Doporučení České vakcinologické společnosti pro pneumokokovou vakcinaci v dospělosti. 2012. [online]. Dostupné z: http://www.vakcinace.eu/doporuceni-a-stanoviska.